Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Three Cases of Encorafenib Treatment for Recurrent BRAF-Mutated Colorectal Cancer].

Gan to kagaku ryoho. Cancer & chemotherapy - 1 Aug 2026

Ozasa Haruka, Nanishi Kenji, Arita Tomohiro, Shimizu Hiroki, Kiuchi Jun, Kurashima Kento, Inoue Hiroyuki, Nishibeppu Keiji, Kubo Hidemasa, Imamura Taisuke, Kosuga Toshiyuki, Yamamoto Yusuke, Konishi Hirotaka, Morimura Ryo, Fujiwara Hitoshi, Shiozaki Atsushi

Abstract excerpt

BACKGROUND: Recently, favorable outcomes from encorafenib treatment have been reported in patients with BRAF-mutated colorectal cancer, which has a poor prognosis. CASES: Encorafenib was administered to three patients with recurrence after surgery for BRAF-mutated colorectal cancer. Encorafenib and cetuximab were administered to 2 patients, and encorafenib, binimetinib, and cetuximab were administered to one...

Read the complete abstract on PubMed

Topics

Humans
Antineoplastic Combined Chemotherapy Protocols
Carbamates
Colorectal Neoplasms
Mutation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Proto-Oncogene Proteins B-raf

Recurrence

Sulfonamides

Source

Identifiers

PMID: 42723244

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Three Cases of Encorafenib Treatment for Recurrent BRAF-Mutated Colorectal Cancer].PMID 42723244Read ↗

[A Case of BRAF Mutant Cecal Cancer Treated with Encorafenib, Binimetinib, and Cetuximab Triple Therapy].Semantic proximity Read ↗

[Two Cases of Recurrent Colon Cancer with BRAF Mutation].Semantic proximity Read ↗

Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series.Semantic proximity Read ↗

[New Treatment Strategies for BRAF Mutation-Positive Colorectal Cancer].Semantic proximity Read ↗

Encorafenib, binimetinib and cetuximab combined therapy for patients with BRAFV600E mutant metastatic colorectal cancer.Semantic proximity Read ↗

BRAF V600E-mutant colorectal cancer with CNS metastases treated successfully with encorafenib, binimetinib and cetuximab.Semantic proximity Read ↗

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal CancerSemantic proximity Read ↗

Unexpected and durable response with regorafenib in a metastatic colorectal cancer patient without KDR mutation: A case report.Semantic proximity Read ↗

[A Case of BRAF V600E-Mutant Colorectal Cancer Treated Effectively by Encorafenib, Binimetinib, and Cetuximab Triple Therapy].Semantic proximity Read ↗

[Long-Term Survival of a Patient with KRAS Mutated Colon Cancer Successfully Treated with Regorafenib].Semantic proximity Read ↗

A Randomized Trial of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or FOLFIRI/Cetuximab in Chinese Patients With BRAFV600E Mutant Metastatic Colorectal Cancer: The NAUTICAL Study.Semantic proximity Read ↗

[Regorafenib in patients with metastatic colorectal cancer: a review and an update].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.